Medical network - March 30 each year on March 30, is a "world day of bipolar disorder," this is jointly initiated by the international organization the world autism day, world alzheimer's day anniversary of the third international disorder. 

 

General situation of 

 

High rate of relapse and two polarity 

 

Bipolar disorder (BPS), also called bipolar disorder. Due to brain disorder in patients with individual mood, energy, and ability to function transformation, is a kind of emotional ups and downs is bigger lifelong disease, there are significant characteristics of manic and depressive. Data according to the WHO, the global incidence of BPS to 1% ~ 3%, some countries can be as high as 5% ~ 7%, about 60 million people suffering from the disease. In 2015, according to the IMS company data in the top 500 global medicine market, nerve psychiatric drugs has amounted to $69.6 billion, 14.25% of the market. 

 

BPS incidence on the rise in our country, Chinese patients with BPS to 1% ~ 1.5% of the total number of people with mental disorders, including shenzhen area rates as high as 1.5%. BPS with high recurrence rate, and the characteristics of the two polar, prescribed drugs is very difficult to bring benefit to patients, to strengthen family psychological support and "cocktail" combination therapy is the key to improve symptoms. 

 

TOP 10 (66.24%) 

 

According to forecast of HDM data, 2016 key cities for the domestic public hospital nerve spiritual medicine overall market size is 15.295 billion yuan, a year-on-year growth of 9.51% a year. Among them, the bipolar disorder drug market size is 2.562 billion yuan, year-on-year growth of 7.82% last year, accounting for 16.75% of the overall market nervous spirit field. 

 

 

 

M senior network database data, predicted in 2016 domestic cities, public hospitals, public hospitals at the county level, the urban community health care, in towns and townships, entity drug stores, shop three terminal BPS treatment market size of 10 billion yuan. 

 

Domestic BPS treatment TOP 10 varieties are: department of olanzapine, ai citalopram, valproic acid, oqa xiping, sertraline, venlafaxine, paroxetine, quetiapine, duloxetine and fluorine pp thiamethoxam tons of beauty QuXin. Forecast in 2016 key cities for the domestic public hospitals need variety medicine amount is 66.24% BPS market. 

 

Four categories of drugs 

 

Bipolar disorder treatments including many kinds of drugs in the field of mental and neurological. On June 6, 2013, the national health development planning commission issued the clinical path of bipolar disorder, BPS treatment can be divided into four categories: 

 

1. The mood stabilizers: clinical commonly used with lithium carbonate, valproic acid salt, lamotrigine, topiramate, carbamazepine and orcas west equality. 2. The second generation antipsychotics: mainly clozapine, olanzapine, quetiapine equality. 3. Antidepressants: a lower preferred drug-induced to mania of serotonin reuptake inhibitors (SSRIs) class of drugs, mainly fluoxetine and paroxetine, sertraline, fluvoxamine, citalopram, venlafaxine, duloxetine, mirtazapine and letrozole ketone, bupropion and fluorine pp beauty QuXin thiamethoxam tons. 4. Benzodiazepine classes: common clonazepam, lorazepam, diazepam, nitrate diazepam, estazolam, alprazolam, also can use a benzodiazepine drugs zopiclone, azole pyrazole, to drugs. 

 

varieties 

 

Mood stabilizers, valproic acid, 10 years increased 7 times 

 

Mood stabilizer is mainly drug manic valproic acid lithium carbonate and antiepileptic drugs, lamotrigine, topiramate, carbamazepine and orcas west eight drugs equals. Forecast in 2016 key cities for the domestic public hospital drug mood stabilizers, amount to 472 million yuan, year-on-year growth rate of 8.11% in the previous year, accounting for 15.93% of bipolar disorder drug market. 

 

Valproic acid sodium (Depakote) is listed on the FDA approved abbott drugs in 1983. In 1995 the FDA approved sodium valproic acid and lithium agent and olanzapine treatment BPS syndrome, around the world by abbott laboratories and sanofi to jointly develop the market. After the patent expires, generics are listed. 2015, novartis Depakine generated sales of around 422 million euros, year-on-year growth of 6.83% a year. 

 

Valproate in 2001 to enter the Chinese market, commodity called DE ba jin, currently registered import drug injection, syrup and zyban. 15 domestic enterprises hold valproate preparation approval, two holding valproic acid magnesium preparations approvals, six hold valproic acid amide approval. 

 

In 2016, according to HDM system data of the urban public hospitals valproic acid salts drug use amount is 248 million yuan, a year-on-year growth of 9.92% a year. Since 2005, valproate in the field of BPS and epilepsy medication was at the top sales, valproate in 2005 samples of domestic hospital drug use amount is only tens of millions of yuan, 10 years, seven times the market growth. 

 

 

 

Domestic valproate imported drugs occupied 60%, Chinese medicine account for 40%. Sanofi "DE ba jin" occupy 60.54%, shenyang new horse pharmaceutical valproic acid sodium injection occupy 18.35%, hunan hunan pharmaceutical "treasure to celebrate" occupy 12.83%, chengdu di kang biological pharmaceutical "than" occupy 10.94%, formed a higher degree of market concentration. Powder injection for injection (47.68%), tablet (45.29%), solution (6.98%), syrups accounted for 0.05%. 

 

Drug manic lithium carbonate tablet in bipolar disorder drug market is also occupy the important position. Forecast in 2016 key cities for the domestic public hospital lithium carbonate sum of nearly 3 million yuan, up 161.73% on the previous year, the TOP 3 manufacturers are: jiangsu en pharmaceutical occupy 59.95%, daughter xiangjiang river of hunan occupy 35.55%, jiangsu lianhuan pharmaceutical occupy 4.28%. It is worth mentioning that jiangsu en present a trend of rapid growth, 2013-2016, three years the average growth rate as high as 168.55%. 

 

 

 

The second generation antipsychotics: olanzapine increased 2.95% 

 

Forecast in 2016 key cities for the domestic public hospital of the second generation antipsychotic medicinal drug amount is 697 million yuan, which is in the lead of olanzapine. 

 

Olanzapine is in 1996 the FDA approved lilly drug to market, commodity called Zyprexa. 2001-2016 global olanzapine total sales of $54 billion. Patents expire after sales, in 2016 sales of Zyprexa to $725 million. 

 

According to forecast of HDM system data, 2016 key cities for the domestic public hospital drug olanzapine amount to 362 million yuan, year-on-year growth rate of 2.95% in the previous year. Currently approved nine domestic enterprises, production and sales of olanzapine, lilly "zyprexa" occupy 40.18%, India nguyen reddy lab "olam" occupy 4.22%, changzhou Watson "about sensitive" occupy 2.61%, jiangsu howson LanNing "o" occupy 52.99%, up 2.18% on the previous year, and eli lilly "zyprexa" fell by 5%. 

 

 

 

Antidepressant: citalopram siege ai division 

 

Is expected in 2016 key cities for the domestic public hospitals for BPS 12 antidepressants market totaled 1.149 billion yuan, year-on-year growth of 9.12% a year. 

 

Escitalopram citalopram is an antidepressant drugs ranks first. Escitalopram citalopram and citalopram is Danish spirit north company branded drugs, goods in the Chinese market, to men, citalopram commodity called xi miao. 

 

HDM system data, predicted in 2016 key cities for the domestic public hospital department of citalopram and drug citalopram amount amounted to 290 million yuan, year-on-year growth rate of 10.9% in the previous year. Citalopram preparations in recent years the market decline year by year, the market was occupied by escitalopram citalopram. 

 

 

 

Benzodiazepine classes: midazolam lead 

 

Forecast in 2016 key cities for the domestic public hospital 15 benzodiazepine drugs drug amount is 183 million yuan, year-on-year growth rate of 17.31% in the previous year. Leading varieties are midazolam. 

 

HDM system data, predicted in 2016 key cities for the domestic public hospital midazolam drug amount is 81.71 million yuan, year-on-year growth rate of 7.96% in the previous year. TOP 10 varieties of high growth rate of 35.36% and the sand diazepam, zopiclone 26.75% right, estazolam, alprazolam, 38.95% to 41.49%.